Carisma Therapeutics Inc. (Nasdaq: CARM), a US-based clinical-stage biopharmaceutical company, announced on Monday that it has named Marella Thorell and David Scadden, MD as its new directors, effective 30 June 2024.

Dr Scadden serves as the Gerald and Darlene Jordan professor of Medicine and professor of Stem Cell and Regenerative Biology at Harvard University. He founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute. He serves as the chairman Emeritus and professor of the Harvard University Department of Stem Cell and Regenerative Biology. He has worked on the board of scientific counsellors for the National Cancer Institute, the board of external experts for the National Heart, Lung, and Blood Institute, the board of directors of the International Society for Stem Cell Research, and is an affiliate member of the Broad Institute of Harvard and MIT. He works on multiple editorial boards, scientific advisory boards, and corporate boards. He serves as a scientific founder of Fate Therapeutics, Inc., and Dianthus Therapeutics, Inc., and also works on the board of directors of Agios Pharmaceuticals, Inc., and Editas Medicine, Inc.

Thorell has over 25 years of extensive experience in finance and operations across both public and private biotech companies. Presently, she is the chief financial pfficer of Seres Therapeutics. She has worked as the chief financial officer of Evelo Biosciences, chief accounting officer at Centessa Pharmaceuticals, chief financial officer of Palladio Biosciences prior to its acquisition by Centessa, and chief financial officer and chief operating officer of Realm Therapeutics. She has served in roles of increasing responsibility at Campbell Soup Company and Ernst & Young, LLP. She is a director and chair of the Audit Committee of ESSA Pharmaceuticals and was earlier chair of the board of Vallon Pharmaceuticals before its merger in 2023.